查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球基因组编辑市场：关注技术分布：行业趋势和预测（2023-2035）
市场调查报告书
商品编码
1411406

全球基因组编辑市场：关注技术分布：行业趋势和预测（2023-2035）

Genome Editing Market: Focus on Technology-Distribution by Type of Gene Editing Technique, Type of Therapy, Gene Editing Approach, Type of Gene Delivery Method, Key Geographical Regions & Distribution: Industry Trends & Global Forecasts, 2023-2035
出版日期: | 出版商: Roots Analysis | 英文 270 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2023年，全球基因组编辑市场规模为35亿美元，预计在预测期内（2023-2035年）复合年增长率为12.6%。

基因编辑（基因替换）是修改（插入、删除、替换）生物体基因组中单一基因（或基因序列）的过程。近年来，编辑基因组内特定位点的需求不断增加，基因编辑公司推出了多种基因组编辑工具——ZFN（锌指核酸□）、TALEN（组织脂肪样效应核酸□）以及最近的 CRISPR （基于cRNA的技术）等-发展正在迅速增加。这些基因编辑工具用于治疗镰状细胞疾病（SCD）、帕金森氏症（PDD）、听力损失（HELP）、週边动脉疾病（PAD）、脊髓性肌肉萎缩症（SMA）和自体免疫疾病（AML ）等疾病. 它已被广泛用作治疗由遗传异常引起的临床症状的纠正策略。人们正在努力创建标靶基因编辑疗法，截至2023年，已有超过300种基因疗法候选药物正在进行临床试验。值得注意的是，预防性治疗也是基因编辑应用市场感兴趣的领域。但必须指出的是，基因编辑药物的开发涉及基因研究领域的大量投资。为了有效率、准确和安全地提供这些药物，製药公司正在依赖基因组编辑公司开发的新基因组编辑技术，从而透过实现必要的基因操作来改善临床结果，这将有助于药物开发商的努力。凭藉令人鼓舞的临床试验结果和加速的药物审批，基因组编辑市场预计在未来几年将显着成长。

本报告对全球基因组编辑市场进行了分析，并概述了治疗方法、市场的基本结构和最新情况、主要的市场促进和限制因素、整体市场规模的趋势展望以及按地区（所有三个我们调查各细分市场的详细趋势、主要业务联盟和资本交易（投资、併购等）的近期动向、专利註册状况、当前竞争状况、主要公司概况等。

主要市场参与者

  • Arcturus Therapeutics
  • Avectas
  • Beam Therapeutics
  • Bio-Sourcing
  • Caribou Biosciences
  • Century Therapeutics
  • CRISPR Therapeutics
  • EdiGene
  • Editas Medicine
  • Flash Therapeutics
  • Fortgen
  • G+FLAS Life Sciences
  • Graphite Bio
  • Intellia Therapeutics
  • Ntrans Technologies
  • OXGENE
  • Prime Medicine
  • Revvity (formerly known as Horizon Discovery)
  • TargetGene Biotechnologies
  • Vor Biopharma
  • ZeClinics

目录

第一章简介

第二章研究方法

第 3 章. 经济和其他专案特定考虑因素

第 4 章执行摘要

第 5 章 简介

  • 基因组编辑概述
  • 基因组编辑技术的应用
  • 其他新兴技术
  • 结论

第六章 技术情况

  • 基因组编辑：技术前景
  • 基因组编辑：技术开发人员现状

第七章技术竞争力分析

  • 先决条件/关键参数
  • 调查方法
  • 技术竞争力分析

第八章公司简介

  • Arcturus Therapeutics
  • Beam Therapeutics
  • Caribou Biosciences
  • Century Therapeutics
  • CRISPR Therapeutics
  • Editas Medicine
  • Graphite Bio
  • Intellia Therapeutics
  • Prime Medicine
  • Vor Biopharma
  • 其他主要公司

第 9 章 伙伴关係与合作

  • 合作模式
  • 基因组编辑技术：伙伴关係与合作

第10章 专利分析

  • 分析范围/方法
  • 基因组编辑领域：专利分析
  • 基因组编辑领域：专利基准分析
  • 专利估值分析

第十一章 融资与投资分析

  • 基金类型
  • 基因组编辑领域：资金与投资分析

第十二章市场影响分析：驱动因素、限制因素、机会、挑战

  • 市场驱动力
  • 市场制约因素
  • 市场机会
  • 市场挑战
  • 结论

第十三章 基因组编辑技术市场

  • 假设和研究方法
  • 基因组编辑技术市场：未来预测（2023-2035）
  • 主要细分市场
  • 动态仪表板

第十四章 基因组编辑技术市场：依基因编辑技术类型划分

  • 主要假设及研究方法
  • CRISPR-Cas系统：预测值（2023-2035）
  • TALEN：预测值（2023-2035）
  • 大范围核酸□：预测值 (2023-2035)
  • ZFN：预测值（2023-2035）
  • 其他方法：预测值（2023-2035）
  • 测量数据

第十五章基因组编辑技术市场：依治疗类型

  • 主要假设及研究方法
  • 细胞疗法：预测值（2023-2035）
  • 基因治疗：预测值（2023-2035）
  • 其他治疗：预测值（2023-2035）
  • 测量数据

第十六章 基因组编辑技术市场：依基因编辑方法

  • 主要假设及研究方法
  • 基因敲除方法：预测价值（2023-2035）
  • 基因敲入方法：预测价值（2023-2035）
  • 测量数据

第十七章 基因组编辑技术市场：以基因传递方式

  • 主要假设及研究方法
  • 体外递送方法：预测值（2023-2035）
  • 体内递送方法：预测值（2023-2035）
  • 测量数据

第十八章 基因组编辑技术市场：以基因转殖方式

  • 主要假设及研究方法
  • 病毒载体：预测值（2023-2035）
  • 非病毒载体：预测值（2023-2035）
  • 测量数据

第十九章 基因组编辑技术市场：依应用领域

  • 主要假设及研究方法
  • 药物发现与开发：预测值（2023-2035）
  • 诊断：预测值（2023-2035）
  • 测量数据

第 20 章 基因组编辑技术市场：依最终使用者类型

  • 主要假设及研究方法
  • 製药和生物技术公司：预测（2023-2035）
  • 学术/研究机构：预测值（2023-2035）
  • 测量数据

第21章基因组编辑技术市场：依主要地区

  • 主要假设及研究方法
  • 北美：预计价值（2023-2035）
  • 欧洲：预计值（2023-2035）
  • 亚太地区：预计价值（2023-2035）
  • 测量数据

第22章基因组编辑技术市场：按所使用的支付方式类型

  • 主要假设及研究方法
  • 里程碑付款：预测值（2023-2035）
  • 预付款：预测（2023-2035）
  • 测量数据

第23章 基因组编辑技术市场：主要市场参与者

  • 产业龙头企业

第24章结论

第25章管理见解

第26章附录1：表格数据

第二十七章 附录2：公司和组织名单

简介目录
Product Code: RA100464

The genome editing marketis valued at USD 3.5 billion in 2023 growing at a CAGR of 12.6% during the forecast period 2023-2035.

Gene editing or gene replacement is the process of modifying (inserting, deleting or replacing) a single gene (or a sequence of genes) in the genome of a living organism. In recent years, the need to edit at a specific site within the genome has increased, there has been a surge in the development of different types of genome editing tools by gene-editing companies. These include ZFNs (zinc finger nucleases), TALENs (tissue-aliphatic-like-effector nucleases) and, most recently, CRISPR (cRNA-based technology). These gene-editing tools have been widely used as a corrective strategy to treat clinical conditions resulting from genetic abnormalities, including Sickle cell disease (SCD), Parkinson's disease (PDD), hearing loss (HELP), peripheral artery disease (PAD), spinal muscular atrophies (SMA), autoimmune diseases (AML) and other types of genetic disorders. In the midst of the current efforts to create targeted gene-editing therapies, there are more than 300 candidates for gene therapy in clinical trials as of 2023. It is worth mentioning, prophylaxis treatment is another segment that has attracted a lot of attention in the market of gene editing applications. However, it is important to note that the development of a gene edited drug product involves a significant investment in the development of drugs in the field of gene research. In order to deliver these drugs efficiently, precisely and safely, the pharma companies are relying on new genome editing technologies developed by the genome editing companies, which in turn will help the drug developers in improving the clinical outcome by achieving the required genetic manipulation. With encouraging clinical trial results and accelerated drug approval, the market for genome editing is expected to experience significant growth over the next few years.

Key Market Segments

Type of Gene Editing Technique

  • CRISPR-Cas System
  • TALENs
  • Meganucleases
  • ZFNs
  • Other Techniques

Type of Therapy

  • Cell Therapies
  • Gene Therapies
  • Other Therapies
  • Gene Editing Approach
  • Gene Knock-Out Approaches
  • Gene Knock- In Approaches
  • Gene Delivery Method
  • Ex-Vivo Delivery Methods
  • In-Vivo Delivery Methods
  • Gene Delivery Modality
  • Viral Vectors
  • Non-Viral Vectors
  • Application Area
  • Drug Discovery and Development
  • Diagnostics

Type of End User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific
  • Payment Method Employed
  • Upfront Payments
  • Milestone Payments

Research Coverage:

The report studies the genome editing market based on type of gene editing technique, type of therapy, gene editing approach, gene delivery method, gene delivery modality, application area, type of end user, key geographical regions and payment method employed.

The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.

The report forecasts the revenue of market segments with respect to three major regions

The report includes a brief introduction to genome editing, including the evolution of the domain over the years, a list of the different genome editing technologies, and an overview of how genome editing is being used in different industries such as biotechnology, pharma and agriculture. It also highlights the various cutting-edge genome editing technologies.

Comprehensive analysis of the current technology landscape for genome editing domain considering parameters such as type of gene editing technique (CRISPR-Cas system, meganucleases, TALENs, ZFNs and other techniques), gene editing approach, type of gene delivery method, type of gene delivery modality, highest phase of drug development supported, therapeutic area and application. In addition, the chapter features information on various technology developers, along with analysis based on multiple parameters, establishment year, company size, headquarters and operational model

Create detailed profiles of leading genome editing companies, including establishment year, employees, HQ location, key executives, technology portfolios, recent developments, and future outlook.

Detailed company competitiveness evaluation of medical aesthetics company, considering developer strength and technology strength in terms of type of gene editing technique, gene editing approach, in-silico (CADD) analysis, type of gene delivery method, type of gene delivery modality, highest phase of development supported and application area.

Examine partnerships (licensing agreements, research and development agreements, technology integration agreements, etc.) in the genome editing market from 2018-2023. Analyze recent investments (grants, funding rounds) and initiatives by market stakeholders.

Review patents related to genome editing from 2018-2023, highlighting types, publication years, locations, CPC symbols, focus areas, applicant types, and leading players.

The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the genome editing market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies

  • Arcturus Therapeutics
  • Avectas
  • Beam Therapeutics
  • Bio-Sourcing
  • Caribou Biosciences
  • Century Therapeutics
  • CRISPR Therapeutics
  • EdiGene
  • Editas Medicine
  • Flash Therapeutics
  • Fortgen
  • G+FLAS Life Sciences
  • Graphite Bio
  • Intellia Therapeutics
  • Ntrans Technologies

    OXGENE

  • Prime Medicine
  • Revvity (formerly known as Horizon Discovery)
  • TargetGene Biotechnologies
  • Vor Biopharma
  • ZeClinics

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Key Market Insights
  • 1.3. Scope of the Report
  • 1.4. Research Methodology
  • 1.5. Frequently Asked Questions
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact / Related Factors
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past

Recessions and Lessons Learnt

      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Introduction to Genome Editing
    • 5.2.1. Evolution of Genome Editing
    • 5.2.2. Genome Editing Technologies
      • 5.2.2.1. CRISPR - Cas System
      • 5.2.2.2. Transcription Activator-Like Effector Nucleases (TALENs)
      • 5.2.2.3. Zinc Finger Nucleases (ZFNs)
      • 5.2.2.4. Meganucleases / Homing Endonucleases
  • 5.3. Applications of Genome Editing Technologies
  • 5.4. Other Emerging Technologies
  • 5.5. Concluding Remarks

6. TECHNOLOGY LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Genome Editing: Technology Landscape
    • 6.2.1. Analysis by Type of Gene Editing Technique
    • 6.2.2. Analysis by Gene Editing Approach
    • 6.2.3. Analysis by Type of Gene Delivery Method
    • 6.2.4. Analysis by Type of Gene Delivery Modality
    • 6.2.5. Analysis by Highest Phase of Drug Development Supported
    • 6.2.6. Analysis by Therapeutic Area
    • 6.2.7. Analysis by Application Area
  • 6.3. Genome Editing: Technology Developer Landscape
    • 6.3.1. Analysis by Year of Establishment
    • 6.3.2. Analysis by Company Size
    • 6.3.3. Analysis by Location of Headquarters
    • 6.3.4. Analysis by Operational Model
    • 6.3.5. Most Active Players: Distribution by Number of Technologies

7. TECHNOLOGY COMPETITIVENESS ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Assumptions / Key Parameters
  • 7.3. Methodology
  • 7.4. Technology Competitiveness Analysis
    • 7.4.1. Genome Editing Technologies Offered by Players based in North America
    • 7.4.2. Genome Editing Technologies Offered by Players based in Europe
    • 7.4.3. Genome Editing Technologies Offered by Players based in Asia-Pacific, Middle East and North Africa, and Latin America

8. COMPANY PROFILES

  • 8.1. Chapter Overview
  • 8.2. Arcturus Therapeutics
    • 8.2.1. Company Overview
    • 8.2.2. Financial Information
    • 8.2.3. Technology Portfolio
    • 8.2.4. Recent Developments and Future Outlook
  • 8.3. Beam Therapeutics
    • 8.3.1. Company Overview
    • 8.3.2. Financial Information
    • 8.3.3. Technology Portfolio
    • 8.3.4. Recent Developments and Future Outlook
  • 8.4. Caribou Biosciences
    • 8.4.1. Company Overview
    • 8.4.2. Financial Information
    • 8.4.3. Technology Portfolio
    • 8.4.4. Recent Developments and Future Outlook
  • 8.5. Century Therapeutics
    • 8.5.1. Company Overview
    • 8.5.2. Financial Information
    • 8.5.3. Technology Portfolio
    • 8.5.4. Recent Developments and Future Outlook
  • 8.6. CRISPR Therapeutics
    • 8.6.1. Company Overview
    • 8.6.2. Financial Information
    • 8.6.3. Technology Portfolio
    • 8.6.4. Recent Developments and Future Outlook
  • 8.7. Editas Medicine
    • 8.7.1. Company Overview
    • 8.7.2. Financial Information
    • 8.7.3. Technology Portfolio
    • 8.7.4. Recent Developments and Future Outlook
  • 8.8. Graphite Bio
    • 8.8.1. Company Overview
    • 8.8.2. Technology Portfolio
    • 8.8.3. Recent Developments and Future Outlook
  • 8.9. Intellia Therapeutics
    • 8.9.1. Company Overview
    • 8.9.2. Financial Information
    • 8.9.3. Technology Portfolio
    • 8.9.4. Recent Developments and Future Outlook
  • 8.10. Prime Medicine
    • 8.10.1. Company Overview
    • 8.10.2. Technology Portfolio
    • 8.10.3. Recent Developments and Future Outlook
  • 8.11. Vor Biopharma
    • 8.11.1. Company Overview
    • 8.11.2. Technology Portfolio
    • 8.11.3. Recent Developments and Future Outlook
  • 8.12. Other Leading Players
    • 8.12.1. Avectas
    • 8.12.2. Bio-Sourcing
    • 8.12.3. Edigene
    • 8.12.4. Flash Therapeutics
    • 8.12.5. Fortgen
    • 8.12.6. G+FLAS Life Sciences
    • 8.12.7. Ntrans Technologies
    • 8.12.8. OXGENE
    • 8.12.9. Revvity (formerly known as Horizon Discovery)
    • 8.12.10. TargetGene Biotechnologies
    • 8.12.11. ZeClinics

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Genome Editing Technologies: Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Year and Type of Partnership
    • 9.3.4. Analysis by Type of Partner
    • 9.3.5. Analysis by Location of Headquarters of Partner
    • 9.3.6. Most Active Players: Analysis by Number of Partnerships
    • 9.3.7. Analysis by Geography
      • 9.3.7.1. Local and International Agreements
      • 9.3.7.2. Intercontinental and Intracontinental Agreements

10. PATENT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Genome Editing Domain: Patent Analysis
    • 10.3.1. Analysis by Publication Year
    • 10.3.2. Analysis by Type of Patent and Publication Year
    • 10.3.3. Analysis by Geography
    • 10.3.4. Analysis by CPC Symbols
    • 10.3.5. Leading Industry Players: Analysis by Number of Patents
  • 10.4. Genome Editing Domain: Patent Benchmarking Analysis
    • 10.4.1. Analysis by Patent Characteristics
    • 10.4.2. Analysis by Leading Industry Players
  • 10.5. Patent Valuation Analysis

11. FUNDING AND INVESTMENT ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Types of Funding
  • 11.3. Genome Editing Domain: Funding and Investment Analysis
    • 11.3.1. Analysis by Year of Investment
      • 11.3.1.1. Cumulative Year-wise Trend of Funding Instances
      • 11.3.1.2. Cumulative Year-wise Trend of Amount Invested
    • 11.3.2. Analysis by Type of Funding
      • 11.3.2.1. Analysis of Funding Instances
      • 11.3.2.2. Analysis of Amount Invested
    • 11.3.3. Analysis by Year and Type of Funding
    • 11.3.4. Analysis by Geography
    • 11.3.5. Most Active Players: Analysis by Amount Invested and Number of Funding Instances
    • 11.3.6. Leading Investors: Analysis by Number of Funding Instances

12. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 12.1. Chapter Overview
  • 12.2. Market Drivers
  • 12.3. Market Restraints
  • 12.4. Market Opportunities
  • 12.5. Market Challenges
  • 12.6. Conclusion

13. GENOME EDITING TECHNOLOGIES MARKET

  • 13.1. Chapter Overview
  • 13.2. Assumptions and Methodology
  • 13.3. Genome Editing Technologies Market, Forecasted Estimates (2023-2035)
    • 13.3.1. Scenario Analysis
  • 13.4. Key Market Segmentations
  • 13.5. Dynamic Dashboard

14. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF GENE EDITING TECHNIQUE

  • 14.1. Chapter Overview
  • 14.2. Key Assumptions and Methodology
  • 14.3. CRISPR-Cas System: Forecasted Estimates (2023-2035)
  • 14.4. TALENs: Forecasted Estimates (2023-2035)
  • 14.5. Meganucleases: Forecasted Estimates (2023-2035)
  • 14.6. ZFNs: Forecasted Estimates (2023-2035)
  • 14.7. Other Techniques: Forecasted Estimates (2023-2035)
  • 14.8. Data Triangulation
    • 14.8.1. Insights from Primary Research
    • 14.8.2. Insights from Secondary Research
    • 14.8.3. Insights from In-house Repository

15. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF THERAPY

  • 15.1. Chapter Overview
  • 15.2. Key Assumptions and Methodology
  • 15.3. Cell Therapies: Forecasted Estimates (2023-2035)
  • 15.4. Gene Therapies: Forecasted Estimates (2023-2035)
  • 15.5. Other Therapies: Forecasted Estimates (2023-2035)
  • 15.6. Data Triangulation
    • 15.6.1. Insights from Primary Research
    • 15.6.2. Insights from Secondary Research
    • 15.6.3. Insights from In-house Repository

16. GENOME EDITING TECHNOLOGIES MARKET, BY GENE EDITING APPROACH

  • 16.1. Chapter Overview
  • 16.2. Key Assumptions and Methodology
  • 16.3. Gene Knock-Out Approaches: Forecasted Estimates (2023-2035)
  • 16.4. Gene Knock-In Approaches: Forecasted Estimates (2023-2035)
  • 16.5. Data Triangulation
    • 16.5.1. Insights from Primary Research
    • 16.5.2. Insights from Secondary Research
    • 16.5.3. Insights from In-house Repository

17. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY METHOD

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Ex-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
  • 17.4. In-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
  • 17.5. Data Triangulation
    • 17.5.1. Insights from Primary Research
    • 17.5.2. Insights from Secondary Research
    • 17.5.3. Insights from In-house Repository

18. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY MODALITY

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Viral Vectors: Forecasted Estimates (2023-2035)
  • 18.4. Non-Viral Vectors: Forecasted Estimates (2023-2035)
  • 18.5. Data Triangulation
    • 18.5.1. Insights from Primary Research
    • 18.5.2. Insights from Secondary Research
    • 18.5.3. Insights from In-house Repository

19. GENOME EDITING TECHNOLOGIES MARKET, BY APPLICATION AREA

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Drug Discovery and Development: Forecasted Estimates (2023-2035)
  • 19.4. Diagnostics: Forecasted Estimates (2023-2035)
  • 19.5. Data Triangulation
    • 19.5.1. Insights from Primary Research
    • 19.5.2. Insights from Secondary Research
    • 19.5.3. Insights from In-house Repository

20. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF END USER

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Pharmaceutical and Biotechnology Companies: Forecasted Estimates (2023-2035)
  • 20.4. Academic and Research Institutes: Forecasted Estimates (2023-2035)
  • 20.5. Data Triangulation
    • 20.5.1. Insights from Primary Research
    • 20.5.2. Insights from Secondary Research
    • 20.5.3. Insights from In-house Repository

21. GENOME EDITING TECHNOLOGIES MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. North America: Forecasted Estimates (2023-2035)
  • 21.4. Europe: Forecasted Estimates (2023-2035)
  • 21.5. Asia-Pacific: Forecasted Estimates (2023-2035)
  • 21.6. Data Triangulation
    • 21.6.1. Insights from Primary Research
    • 21.6.2. Insights from Secondary Research
    • 21.6.3. Insights from In-house Repository

22. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF PAYMENT METHOD EMPLOYED

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. Milestone Payments: Forecasted Estimates (2023-2035)
  • 22.4. Upfront Payments: Forecasted Estimates (2023-2035)
  • 22.5. Data Triangulation
    • 22.5.1. Insights from Primary Research
    • 22.5.2. Insights from Secondary Research
    • 22.5.3. Insights from In-house Repository

23. GENOME EDITING TECHNOLOGIES MARKET: LEADING INDUSTRY PLAYERS

  • 23.1. Chapter Overview
  • 23.2. Leading Industry Players

24. CONCLUSION

25. EXECUTIVE INSIGHTS

26. APPENDIX 1: TABULATED DATA

27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS